Hypomenstrual disorders associated with chronic stress: non-hormonal treatment options

@article{tatarchuk2026hypomenstrual,
  title = {{Hypomenstrual disorders associated with chronic stress: non-hormonal treatment options}},
  author = {T.F. Tatarchuk and N.V. Kosei and S.I. Regeda and T.M. Tutchenko and T.E. Krysenko and H.A. Hordiienko},
  journal = {Репродуктивная эндокринология},
  year = {2026},
  month = sep,
  doi = {10.18370/2309-4117.2026.85.25-36},
  url = {https://doi.org/10.18370/2309-4117.2026.85.25-36},
  note = {CC BY},
}

TY  - JOUR
TI  - Hypomenstrual disorders associated with chronic stress: non-hormonal treatment options
AU  - T.F. Tatarchuk
AU  - N.V. Kosei
AU  - S.I. Regeda
AU  - T.M. Tutchenko
AU  - T.E. Krysenko
AU  - H.A. Hordiienko
PY  - 2026
DA  - 2026/09/01
JO  - Репродуктивная эндокринология
DO  - 10.18370/2309-4117.2026.85.25-36
UR  - https://doi.org/10.18370/2309-4117.2026.85.25-36
AB  - Objective of the study: to evaluate the clinical effectiveness of complex non-pharmacological anti-stress therapy used as monotherapy and in combination with the herbal complex Tazalok in women with hypomenstrual syndrome, based on a comprehensive assessment of changes in menstrual function, ultrasonographic characteristics of the pelvic organs, quality-of-life indicators and laboratory evaluation of the hormonal profile over a six-month follow-up period. Materials and methods. The study included 100 women aged 18–40 years with hypomenstrual syndrome who were divided into two groups of 50 patients each. Women in Group I received non-pharmacological therapy for 6 months, including psychological support, lifestyle modification, nutritional correction, and optimization of physical activity. Patients in Group II additionally received Tazalok at a dose of 45 drops twice daily for 6 months. Clinical and ultrasound assessments were performed at baseline and after 1, 3, and 6 months of treatment. Serum levels of follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone, prolactin, and cortisol were assessed, while quality of life was evaluated using the SF-36 questionnaire. Results. After 6 months of treatment, menstrual function was restored in 84% of patients in Group II compared with 70% in Group I. A regular menstrual cycle was observed in 78% and 52% of women, respectively (p < 0.05). According to ultrasound monitoring, ovulatory cycles after 6 months were detected in 60% of patients in Group II and 42% in Group I; however, the between-group difference did not reach statistical significance (p > 0.05). In contrast, laboratory-confirmed restoration of ovulation based on serum progesterone levels was observed in 68% of women in Group II versus 40% in Group I (p < 0.05). Patients who additionally received Tazalok demonstrated more pronounced positive changes in follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone levels, as well as a reduction in cortisol concentration. At 6 months, all assessed SF-36 domain scores were significantly higher in Group II compared with Group I (p < 0.05). Conclusions. The use of complex phytotherapy with anti-stress, anti-inflammatory, and hormone-modulating effects in combination with psychological counseling in women of reproductive age with hypomenstrual syndrome contributed to a faster and more complete restoration of menstrual and ovulatory function, favorable changes in the hormonal profile, and improvement in the physical, psycho-emotional, and social components of quality of life compared with non-pharmacological therapy alone. These findings indicate a comprehensive effect of Tazalok on the clinical and neuroendocrine manifestations of hypomenstrual syndrome and support its use as a component of complex therapy.
SN  - 2309-4117
SN  - 2411-1295
ER  -